GENO-25HYPERMUTATION AND MALIGNANT PROGRESSION IN AN EXPANDED COHORT OF TEMOZOLOMIDE-TREATED LOW-GRADE GLIOMA PATIENTS
Tali Mazor(Dana-Farber Cancer Institute), J Costello(University of California, San Francisco), Henrik Bengtsson(University of California, San Francisco), Adam B. Olshen(University of California, San Francisco), Joanna J. Phillips(University of California, San Francisco), Kevin Petrecca(McGill University Health Centre), Sarah J. Nelson(Research Institute of Radiology), Emily G. Hamilton(Stanford University), Manish K. Aghi(Neurological Surgery), Andrew W. Bollen(University of California, San Francisco), Jennifer Clarke(Cornell University), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), Brett Johnson(University of California, San Francisco), Lindsey Jones(University of California, San Francisco), Ana Xavier‐Magalhães(University of California, San Francisco), Matthew Grimmer(Sequenom (United States)), Susan M. Chang(University of California, San Francisco), Chibo Hong(Universidad Católica de Santa Fe), Ivan Smirnov(University of California, San Francisco), Mitchel S. Berger(University of California, San Francisco)
Cited by 2
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
The NIH Roadmap Epigenomics Mapping Consortium
|Nature Biotechnology|2010|2k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis
|Journal of Clinical Oncology|2012|1k